A new drug called “fasenediol” has started a phase 3 trial — which means it passed the trials for fewer than 100 patients and is now being rolled out to hundreds to thousands of patients. It has a completely new method of action to combat anxiety — it is to be hoped it will prove to be effective in this phase three trial, and be made available to the public in a few years.
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 https://www.vistagen.com/news-releases/news-release-details/vistagen-initiates-palisade-3-phase-3-study-fasedienol-acute